Its First Drug In Clinic, Kineta Inc. Keeps Raising Cash From Odd Sources

Seattle biotech company Kineta keeps adding to its fundraising pool in unexpected ways. The firm announced Thursday it has raised $10 million from a group of companies that also happen to be its drug development partners. Kineta has leaned on nontraditional investors and other funding sources since its 2007 founding. “I wouldn’t say we’ve deliberately steered clear of VCs,” said Kineta president and CEO Chuck Mangess.